NCT05218499 2026-03-02
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 2/3 Completed
Clinical Trials
10 trialsNCT06058793 2026-01-09
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 3 Completed
NCT05496569 2025-11-21
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT04557449 2025-10-01
CDK4i
Pfizer
Phase 2 Active not recruiting
NCT06789172 2025-09-05
INVOKE
Epkin
Phase 1 Recruiting
NCT06299163 2025-07-23
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Phase 1 Terminated
NCT02451943 2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3 Completed
NCT06115681 2025-07-10
Real-world Study of Dedifferentiated Liposarcoma Patients in China
Boehringer Ingelheim
Completed
NCT05580588 2025-06-13
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Shanghai Pharma Biotherapeutics USA Inc.
Phase 2 Terminated
NCT06578624 2025-06-05
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Lamassu Bio Inc
Phase 1/2 Recruiting